Claims for Patent: 8,183,217

Summary for Patent: 8,183,217

Title:	Methods and means for obtaining modified phenotypes
Abstract:	Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eukaryotic cells by providing aberrant, preferably unpolyadenylated, target-specific RNA to the nucleus of the host cell. Preferably, the unpolyadenylated, target-specific RNA is provided by transcription of a chimeric gene comprising a promoter and a DNA region encoding the target-specific RNA.
Inventor(s):	Waterhouse; Peter Michael (Canberra, AU), Wang; Ming-Bo (Canberra, AU)
Assignee:	Commonwealth Scientific and Industrial Research Organisation (Campbell, AU)
Application Number:	11/179,504
Patent Claims:	1. A method for expressing an unpolyadenylated hairpin RNA in an animal cell, the method comprising the step of providing to an animal cell in culture a DNA comprising a promoter operably linked to a target specific DNA region encoding the unpolyadenylated hairpin RNA, wherein the unpolyadenylated hairpin RNA comprises a target specific sense nucleotide sequence and a target specific antisense nucleotide sequence, wherein the target specific antisense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the complement of a part of an RNA molecule transcribed or produced from a nucleic acid of interest in the animal cell, wherein the target specific sense nucleotide sequence consists of about 20 consecutive nucleotides in a sequence identical to the sequence of the part of the RNA molecule transcribed or produced from the nucleic acid of interest, and wherein the target specific sense nucleotide sequence and the target specific antisense nucleotide sequence are complementary to each other, so as to form in the nucleus of the animal cell the unpolyadenylated hairpin RNA. 2. The method of claim 1, wherein the target specific sense nucleotide sequence corresponds to one or more consecutive exons of the nucleic acid of interest. 3. The method of claim 1, wherein the target specific sense nucleotide sequence corresponds to a translated region of the nucleic acid of interest. 4. The method of claim 1, wherein the target specific sense nucleotide sequence corresponds to an untranslated region of the RNA produced from the nucleic acid of interest. 5. The method of claim 1, wherein the promoter is recognized by a eukaryotic RNA polymerase I or III and the DNA further comprises a terminator for the polymerase I or III. 6. The method of claim 1, wherein the nucleic acid of interest is a gene incorporated in the genome of the animal cell. 7. The method of claim 1, wherein the nucleic acid of interest is an endogenous gene of the animal cell. 8. The method of claim 1, wherein the nucleic acid of interest is a viral nucleic acid. 9. The method of claim 1, wherein the unpolyadenylated RNA lacks a 5' cap structure. 10. The method of claim 1, comprising the steps of a) introducing a DNA into the nucleus of the animal cell, the DNA encoding the unpolyadenylated hairpin RNA, and b) observing a phenotype of the animal cell by a suitable method; thereby identifying a phenotype associated with the expression of the nucleic acid of interest in the animal cell. 11. The method of claim 10, wherein the phenotype is observed after culturing of the animal cell. 12. The method of claim 10, wherein the phenotype is a modified profile of metabolites synthesized in the animal cell. 13. The method of claim 1, wherein the animal cell is a human cell. 14. The method of claim 1, wherein the promoter is a constitutive promoter. 15. The method of claim 1, wherein the promoter is an inducible promoter. 16. The method of claim 1, wherein the promoter is a tissue-specific promoter. 17. The method of claim 1, wherein the promoter is recognized by a single subunit RNA polymerase from a bacteriophage. 18. The method of claim 1, wherein the nucleic acid of interest is a transgene that has been introduced into the animal cell. 19. The method of claim 1, wherein the unpolyadenylated hairpin RNA comprises a persistent intron. 20. The method of claim 5, wherein the promoter is recognized by a eukaryotic RNA polymerase III and the DNA further comprises a terminator for the polymerase III.

Details for Patent 8,183,217

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2019-08-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2019-08-13